Servier full year 2021/22 results confirm the transformation trajectory

French privately-held pharma company Servier has announced its financial results for the 2021/22 financial year, highlighting the major steps of its ongoing transformation.

Servier Group’s consolidated sales revenue for the 2021/22 financial year were up 9.8% compared to the 2020/21 financial year, reaching 4.876 billion euros ($5.29 billion). This performance was driven by a 7.6% increase in global sales volumes and a favorable exchange rate of 3.2% (+140 million euros in 2021/22 versus a negative impact of -156 million euros the previous year). The complex price pressure environment had a 1% negative effect on revenue growth, an impact of 45 million, Servier noted.

Earnings before interest, tax, depreciation and amortization (EBITDA) for the 2021/22 financial year amounted to 859 million euros, up 34.6%, and represented 17.6% of the group revenue, compared with 14.4% for the previous financial year. Recurring operating result for 2021/22 amounted to 442 million euros and represented 9.1% of group sales revenue. This performance was driven by an increase in international revenue and a favorable effect of exchange rates coupled with very good expenditure control and prioritizations made during the financial year. Net income sharply increased to 192 million euros, or 3.9% of group sales revenue, compared with a loss of 95 million euros the previous financial year.